Next Article in Journal
Mass-Spectrometry Based Proteome Comparison of Extracellular Vesicle Isolation Methods: Comparison of ME-kit, Size-Exclusion Chromatography, and High-Speed Centrifugation
Previous Article in Journal
Hypermethioninemia Leads to Fatal Bleeding and Increased Mortality in a Transgenic I278T Mouse Model of Homocystinuria
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 8
Issue 8
10.3390/biomedicines8080245
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

by
Motoki Eguchi
1,
Yosuke Minami
1,*,
Ayumi Kuzume
1,2 and
SungGi Chi
1
1
Department of Hematology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
2
Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa 296-8602, Japan
*
Author to whom correspondence should be addressed.
Biomedicines 2020, 8(8), 245; https://doi.org/10.3390/biomedicines8080245
Submission received: 11 June 2020 / Revised: 10 July 2020 / Accepted: 16 July 2020 / Published: 24 July 2020
(This article belongs to the Section Tumor Cell Biology)
Browse Figures
Versions Notes

Abstract

:
FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib and quizartinib show excellent response rates in patients with FLT3-mutated AML, but its duration of response may not be sufficient yet. The majority of cases gain secondary resistance either by on-target and off-target abnormalities. On-target mutations (i.e., FLT3-TKD) such as D835Y keep the TK domain in its active form, abrogating pharmacodynamics of type II FLT3 inhibitors (e.g., midostaurin and quizartinib). Second generation type I inhibitors such as gilteritinib are consistently active against FLT3-TKD as well as FLT3-ITD. However, a “gatekeeper” mutation F691L shows universal resistance to all currently available FLT3 inhibitors. Off-target abnormalities are consisted with a variety of somatic mutations such as NRAS, AXL and PIM1 that bypass or reinforce FLT3 signaling. Off-target mutations can occur just in the primary FLT3-mutated clone or be gained by the evolution of other clones. A small number of cases show primary resistance by an FL-dependent, FGF2-dependent, and stromal CYP3A4-mediated manner. To overcome these mechanisms, the development of novel agents such as covalently-coupling FLT3 inhibitor FF-10101 and the investigation of combination therapy with different class agents are now ongoing. Along with novel agents, gene sequencing may improve clinical approaches by detecting additional targetable mutations and determining individual patterns of clonal evolution.

1. Introduction

FMS-like tyrosine kinase 3 (FLT3) is classified as a type 3 receptor tyrosine kinase, along with KIT, FMS, and PDGFR [1,2,3]. FLT3 is composed of an extracellular region consisting of five immunoglobulin-like domains, and an intracellular region consisting of a juxtamembrane (JM) domain, two tyrosine kinase (TK) domains, and a C-terminal domain. FLT3 is expressed in normal hematopoietic stem cells and progenitor cells, and is dimerized upon binding with either membrane-bound or soluble FLT3 ligands (FLs) produced by bone marrow stromal cells, which subsequently causes the phosphorylation and activation of tyrosine residues in the activation-loop (A-loop) [4,5]. Phosphorylated FLT3 activates multiple intracellular signaling pathways involved in the survival, proliferation, and differentiation of hematopoietic stem cells, such as RAS/MAPK, PI3K/Akt/mTOR, and JAK/STAT5 [6,7,8,9]. Since FLT3 is frequently expressed in leukemic cells, FL stimulation induces proliferation and inhibits apoptosis in these cells [10,11]. In 1996, an internal tandem duplication in the JM domain-encoding region of FLT3 (FLT3-ITD) was identified in acute myeloid leukemia (AML) cells [12]. Thereafter, several types of mutations, including point mutations, deletions, and insertions have been detected around the D835 residue in the TK domain (FLT3-TKD) [13]. FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of AML cases, respectively [14,15,16]. Although both FLT3-ITD and FLT3-TKD are gain-of-function mutations, the upregulation of STAT5 was only observed in FLT3-ITD cell lines (32D/ITD) [17]. STAT5 positively regulated Pim-1, which eventually activated mTOR and Mcl-1, which consequently conferred resistance to Akt inhibition in FLT-ITD cell lines [18]. An experiment using transgenic mice with FLT3-ITD-positive hematopoietic stem cells revealed the clear promoting effects of nuclear factors in activated T-cells (NFATC1), a family of inflammatory transcriptional factors, on FLT3-ITD-driven precursor cell expansion and resistance to FLT3 inhibitors [19]. Recent studies suggest that circulating MYBL2, encoded by the cell-cycle checkpoint gene MYBL2, is detected in AML patients with FLT3-ITD mutations and is closely related to mutant FLT3 expression as well as to tumor cell activity [20]. Unlike FLT3-ITD consistently upregulating JAK/STAT signaling, FLT3-TKD enhance SHP1 and SHP2 activity that negatively regulate JAK signaling [21,22]. This may at least partially explain why FLT3-ITD showed more potent myeloproliferative advantages than those of FLT3-TKD in a mouse model [23,24]. The dual mutation of FLT3-ITD and -TKD (FLT3-ITD-TKD) has been found in a small population. A recent study showed that FLT3-ITD-TKD has the ability to activate STAT5, resulting in Bcl-x and RAD51 upregulation that accounts for drug resistance [25]. Since FLT3 mutations are frequently detected in AML and are associated with poor prognosis, this gene is considered a promising molecular target for AML [26,27]. It has been 20 years since abnormalities in the FLT3 were first discovered, and the application of FLT3 inhibitors in clinical settings in Japan, Europe, and the United States has resulted in a paradigm shift in the treatment of FLT3-mutated AML. However, resistance to FLT3 inhibitors has also been reported concomitantly. Mechanisms of the resistance and strategies to overcome it have been vigorously studied and ever-reviewed [28,29,30]. Along with the comprehensive understanding of pathologic FLT3 signaling and the acquired alterations responsible for drug-resistance, non-FLT3 abnormalities that may be closely associated with leukemic clone evolution are revealing its importance, suggesting new approaches. In this review, we summarize our current understanding of resistance to FLT3 inhibitors and discuss the strategies for overcoming this issue.

2. Prognostic Impact of FLT3 Mutations

FLT3-ITD mutation has been recognized as one of the major adverse prognostic factors with nearly twice the increase in hazard ratio [31]. As mentioned in the European LeukemiaNet (ELN) recommendations [27], high allelic burden (generally indicating 50% or more) of FLT3-ITD (FLT3-ITDhigh) is consistently associated with worse prognosis [32,33,34]. On the other hand, the low allelic frequency of FLT3-ITD (FLT3-ITDlow) concomitant with NPM1 mutation possibly leads to favorable prognosis [35], though it has been fraught with controversy [36,37,38]. FLT3-ITDhigh with wild type NPM1 and FLT3-ITDlow with mutated NPM1 are classified as intermediate-risk [27]. Unlike FLT3-ITD, the prognostic significance of FLT3-TKD has not been determined [32,39]. With the development of potent FLT3 inhibitors, better clinical outcomes would be expected, especially in patients with FLT3-ITDhigh. Indeed, previously untreated FLT3-ITDhigh patients who received intensive chemotherapy with sorafenib, a FLT3 inhibitor, showed no significant but seemingly better relapse-free and overall survival than those with FLT3-ITDlow AML [34]. It is not fully known if the FLT3 allelic burden affects the properties in acquiring resistance to FLT3 inhibitors. However, given a certain somatic mutation will belong to a single clone, a larger proportion of mutant FLT3 allele may link to less divergent leukemic clones and vice versa, which theoretically affect drug sensitivity, relapse rates and eventually survival rates. Zhang and his colleagues graphically displayed the clonal evolutions of two individual cases; one for a single clone with a high frequency of FLT3-TKD that later relapsed with an additional mutation within the same clone and the other for complex clones not associated with first-detected FLT3-ITD mutation with low frequency [40]. The prognostic impact of FLT3 mutations and its allele frequency possibly be changed in the era of FLT3 inhibitors.

3. Classification of FLT3 Inhibitors by Its Pharmacodynamics

As first-generation FLT3 inhibitors, existing TK inhibitors such as tandutinib (CT53518), lestaurtinib (CEP-701), sunitinib (SU11248), midostaurin (PKC412), and sorafenib (BAY 43-9006), which can effectively inhibit FLT3 kinase have been studied [41,42,43,44,45]. Thereafter, the compounds with higher selectivity and inhibitory activity were identified. Gilteritinib (ASP2215), quizartinib (AC220), and crenolanib (CP868596) were developed as second-generation FLT3 inhibitors [46,47,48,49,50]. These FLT3 inhibitors are roughly classified into two types (i.e., type I and type II) based on their binding mode to FLT3 molecules. The conformation of the three amino acid residues Asp–Phe–Gly (DFG) in the A-loop of the FLT3 molecule is altered in accordance with the phosphorylation status of the tyrosine residue, which leads to the formation of an active DFG-in conformation or an inactive DFG-out conformation [51,52,53]. Type I inhibitors bind to the ATP-binding site and its vicinity, and subsequently bind with molecules in both DFG-in and DFG-out conformations. Since the molecular homology of various TKs is high and the ATP-binding sites are highly conserved among kinases, type I inhibitors are often less selective. In contrast, type II inhibitors bind to the target kinase by utilizing the hydrophobic space that appears in the proximity of the ATP-binding site in the DFG-out conformation. Since the hydrophobic space in this structure varies significantly between various kinases, type II inhibitors are expected to be more selective than type I inhibitors and are unable to inhibit activated kinases in the DFG-in conformation. Midostaurin, gilteritinib, and crenolanib are type I inhibitors, while quizartinib and sorafenib are type II inhibitors [54]. FLT3-TKD maintains a constant DFG-in conformation owing to alterations in the TK domain, whereas FLT3-ITD can exist in both active DFG-in conformation and inactive DFG-out conformation. Therefore, while type I inhibitors inhibit both FLT3-TKD and FLT3-ITD, type II inhibitors only inhibit FLT-ITD owing to the differences in binding properties, with a few exceptions in first-generation agents (e.g., midosutaurin and sunitinib). For example, TK domain-altering D835 point mutations confer resistance to a type II second-generation inhibitor quizartinib, but not to type I gilteritinib and crenolanib [55]. However, a “gatekeeper” mutation F691L shows universal resistance to all the currently available FLT3 inhibitors [47,49,56,57,58,59]. The characteristics of the FLT3 inhibitors are summarized in Table 1.

4. Current Clinical Role of FLT3 Inhibitors

Among a number of tyrosine kinase inhibitors active against pathologic FLT3 signaling, gilteritinib and midostaurin are now available for the treatment of FLT3-mutated AML in most developed countries. Quizartinib is currently available only in Japan. Stone and his colleagues reported a randomized phase 3 trail, RATIFY, where midostaurin or placebo were added to standard therapy in patients with newly diagnosed FLT3-mutated AML [73]. The midosutaurin group showed longer survival (hazards ration (HR) 0.78) and improved event-free interval (HR 0.78) than the counterpart. Recently, the combination of midostaurin and standard therapy followed by midostaurin maintenance also showed better outcomes compared with historical controls (HR 0.58 in event-free survival) [74]. Efficacy of single-agent gilteritinib for relapsed/refractory FLT3-mutated AML was proved in a randomized phase 3 trial, ADMIRAL [75]. The median overall survival was significantly longer in the gilteritinib group than the conventional chemotherapy group (9.3 months vs. 5.6 months), with a higher percentage of patients who underwent allo-stem cell transplantation (SCT) (26% vs. 15%). However, the median event-free interval was less than 3 months. Similarly, the phase 3 QuANTUM-R trial showed the superiority of single-agent quizartinib over salvage chemotherapy in the same situation (HR 0.76 in overall survival) [76]. Quizartinib has also been tested in the first-line setting and showed activity in a phase 1 trial [77]. In addition to the approved drugs mentioned above, other FLT3 inhibitors also have displayed clinical benefits. Published trials and their primary results are summarized in Table 2. Sorafenib, already approved for renal cell cancer, thyroid cancer and hepatocellular carcinoma, were evaluated in either in a first-line and salvage situation combined with chemotherapy and HMAs (hypomethylating agents), showing promising results [78,79,80,81,82,83,84]. A novel second-generation FLT3 inhibitor crenolanib has shown possible benefits in combination with conventional chemotherapy, in either first-line and salvage treatment [85,86,87]. Lestaurtinib, however, failed to display clinical benefit when administered as maintenance therapy following standard treatment [88,89].

5. Mechanisms of Resistance to FLT3 Inhibitors

5.1. Primary Resistance

Resistance to FLT3 inhibitors can be classified as primary resistance (innate resistance) and secondary resistance (acquired resistance). In primary resistance, the effect of FLT3 inhibitors are prevented during the initial administration in an FL-dependent, FGF2-dependent, and stromal CYP3A4-mediated manner as well as by the activation of other signaling pathways (Figure 1). Most FLT3-mutant AML cells also express wild-type (WT) FLT3 concomitantly. Since WT-FLT3 is sensitive to FL and is affected negligibly by FLT3 inhibitors, FL secretion in the bone marrow microenvironment leads to the activation of the FLT3/MAPK pathway and provides survival signals to AML cells during induction and consolidation therapy. Indeed, certain studies have demonstrated that the co-existence of WT-FLT3 attenuated the anti-tumor effects of FLT3 inhibitors on FLT3-mutated AML cells in vitro and in vivo [88,90,91]. In addition to FL, other cytokines, growth factors, and soluble proteins from the bone marrow microenvironment have been studied with respect to their resistance against quizartinib. For example, fibroblast growth factor 2 (FGF2) induces resistance by activating FGFR1 and inducing downstream MAPK signaling. FGF2 expression in bone marrow stromal cells increased in patients with FLT3-ITD-positive AML treated with quizartinib and was maximized prior to clinical relapse and the induction of resistance mutations [92]. CXCL12, a chemokine expressed by osteoblasts in the bone marrow, is a ligand of CXCR4 expressed by hematopoietic stem cells as well as AML cells. Certain reports revealed that the CXCR4 antagonist plerixafor (AMD 3100) selectively reduced the proliferation of FLT3-ITD AML blasts and increased the sensitivity of FLT3-mutated leukemic cells to the apoptogenic effects of FLT3 inhibitors [93,94]; therefore, the activation of the CXCL12/CXCR4 axis may also induce resistance to FLT3 inhibitors in AML cells. The inactivation of TKIs by CYP3A4 is well established. In particular, hepatic CYP3A4 inactivates all TKIs, including FLT3 inhibitors. Additionally, the expression of CYP3A4 in bone marrow stromal cells attenuated the activity of three different FLT3 inhibitors (sorafenib, quizartinib, and gilteritinib) in FLT3-ITD-positive AML [95].

5.2. Secondary Resistance Due to Additional FLT3 Mutations (on-Target Resistance)

Secondary resistance negates the effects of FLT3 inhibitors via the abnormalities acquired by FLT3 inhibition, such as additional mutations in FLT3 (“on-target” resistance) and defective factors apart from FLT3 (“off-target” resistance). Several genetic mutations associated with FLT3 inhibitor resistance have been reported in clinical trials on FLT3 inhibitors. As mentioned earlier, since type II inhibitors originally have no affinity for FLT3-TKD, additional mutations in the TK domain can confer resistance via the elimination of the inhibitory effect on FLT3-ITD. In cases of recurrence after quizartinib treatment in patients with FLT3-ITD-positive AML, secondary mutations at D835 and Y842 residues as well as at the commonly known “gatekeeper residue” F691 in the kinase domain have been reported (Figure 1) [96]. In vitro, Ba/F3 cells expressing FLT3-ITD and one additional TKD mutation, detected in patients with clinical resistance (+D835Y, +D835V, +Y842C, +Y842H, or +F691L), exhibited resistance to the growth inhibitory effect and dephosphorylation activity of quizartinib. These resistance mutations in the A-loop were also observed in patients treated with sorafenib, another type II inhibitor. Furthermore, during the treatment with gilteritinib and crenolanib (a type I inhibitor), the additional appearance of FLT3-TKD mutations in patients with resistance was infrequent, although the appearance of F691L, a gatekeeper mutation, was observed (Figure 2).
Although the FLT3-F837K and FLT-C35S mutations occurred after the gilteritinib treatment in one patient each, both were considered silent mutations as these did not induce self-proliferation in Ba/F3 cells40. Among the 50 resistant patients treated with crenolanib, five FLT3 (D200N, K429F, Y572C, L601F, and F691L) mutations were observed in six patients; the D200N and L601F mutations did not result in leukemia [40]. Since the frequency of the acquired mutations in FLT3-ITD in patients with clinical resistance to quizartinib, a type II inhibitor, was 50% or less, other resistance mechanisms are also anticipated. In four out of eight patients treated with quizartinib, one or more resistance mutations were observed in the TK domain [96]. In addition to FLT3-ITD alleles, mutations in the TK domain of the original FLT3 allele were detected in seven individuals. Notably, the patients exhibited different frequencies of mutations between the original FLT3 allele and the FLT-ITD allele. In this study, the AML cells collected from one quizartinib-resistant patient did not acquire resistance mutations in either the original FLT3 allele or the FLT3-ITD allele. No mutations were detected in the genes apart from FLT3, although the existence of off-target resistance mechanisms was considered in this patient. These findings suggest the existence of a polyclonal resistance mechanism in patients with AML that relapses after quizartinib treatment.

5.3. Secondary Resistance Due to Non-FLT3 Abnormalities (off-Target Resistance)

Resistant clones formed after treatment with gilteritinib and crenolanib, and a type I inhibitor that exerts an inhibitory effect on FLT3-TKD, have characteristics that are different from those observed after treatment with type II inhibitors. In a comparative genetic analysis before and after relapse in patients treated with gilteritinib, several distinct patterns of clonal selection were observed during the treatment period with gilteritinib [97]. In five out of 41 (12.2%) gilteritinib-resistant patients, FLT3 mutations were not observed in AML cells after the gilteritinib treatment; however, mutations in the RAS/MAPK pathway were present in all of the patients. These results suggest that mutant FLT3-negative clones acquire mutations in the RAS/MAPK pathway and expand as resistant clones. In 36 other patients, the resistant clones contained the original FLT3 mutation, and five of them acquired an F691L TKD mutation in addition to the original FLT3 mutation. In 10 out of the 36 patients with the original FLT3 mutation, additional mutations in the RAS/MAPK pathway, such as NRAS, KRAS, PTPN11, CBL, and BRAF mutations, were acquired. Of note, the mutations in the RAS/MAPK pathway and FLT-F691L mutations were mutually exclusive. In vitro experiments conducted in MOLM-14, an AML cell line with FLT3-ITD, where either mutant RAS or FLT3-F691L was transduced into the parental cells and gilteritinib was administered at low/high-dose (25 and 250 nmol/L), suggested that the RAS-mutant clones were more likely selected by the high concentration of the inhibitor, besides the FLT3-F691L which was more likely to be selected by a low one. Similar to RAS mutations [97,98], the activation of Axl-1, a member of the TAM family of receptor TKs, may also contribute to FLT3-resistance by constantly activating the RAS/MAPK and PI3K/Akt/mTOR pathway. Axl-1 was observed to be highly phosphorylated in midosutaurin-resistant AML cell lines and its resistance was diminished by the Axl-1 inhibition in vitro [99]. In another experiment, patient-derived AML cells with FLT3-ITD were co-cultured with stromal cells and treated with quizartinib [100]. The surviving cells underwent STAT5 activation, which consequently upregulated AXL, which was further enhanced by the hypoxic environment. Conversely, in patients eliciting poor response to crenolanib, several abnormalities have been observed in the loci encoding epigenetic regulators and granulocyte transcription factors, as well as in the cohesin complex. In particular, NRAS, STAG2, CEBPA, ASXL1, and IDH2 mutations were observed in FLT3-WT clones [40]. These findings suggest that the clones escaped and expanded during crenolanib therapy. However, TET2, IDH1, and TP53 mutations occurred simultaneously in FLT3-mutated clones during crenolanib treatment. These results suggest that the off-target resistance mechanism is more frequent when using type I inhibitors, such as gilteritinib or crenolanib, than type II inhibitors. Besides, IDH1 inhibitor ivosidenib [101] and IDH2 inhibitor enasidenib [102,103], both approved by the FDA, are active against IDH1/2-mutant relapsed/refractory AML, though the significance of co-existing FLT3 mutations is not fully understood. In addition, the upregulation of the PI3K/AKT/mTOR pathway in resistant cell lines treated with sorafenib has also been reported [104]. Pim-1 is a proto-oncogene originally detected in hematopoietic cells that functions downstream of STAT5 [105]. Its overexpression induced resistance to lestaurtinib in BaF3/ITD cells and in samples collected from FLT3-ITD-positive patients [106]. Additionally, Pim kinase overexpression has been observed in the samples collected post sorafenib administration in patients with FLT3-ITD-positive AML compared to the levels observed in the samples collected before administration [107]. Pim-1 was associated with an increased expression of anti-apoptosis proteins, such as Bcl-2, BCL-XL, and MCL-1, in FLT3 inhibitor-resistant cases [25,108,109,110]. In particular, the observed resistance may be partly induced by Pim-1. Off-target abnormalities along with FLT3 signaling are schematically summarized in Figure 3.

6. Strategies to Overcome Resistance to FLT3 Inhibitors

6.1. Development of Novel Agents

Previous reports suggest that on-target resistance tends to occur in patients after type II inhibitor treatment, while off-target resistance is likely to occur after type I inhibitor treatment. Since these reports are currently limited to patients recruited during clinical trials, for a better understanding of the mechanism underlying the resistance to each FLT3 inhibitor, it is necessary to determine the characteristics of patients with resistance in real-word settings. In addition, to counter the gatekeeper mutation (F691L) in FLT3, which confers resistance to all existing FLT3 inhibitors, it is necessary to develop a novel FLT3 inhibitor. As described above, while type I inhibitors can also inhibit FLT3-TKD, they exhibit low selectivity, whereas although type II inhibitors cannot inhibit FLT3-TKD, they exhibit high selectivity. FLT3-TKD inhibitory activity and FLT3 selectivity share a trade-off relationship. To resolve these issues, a novel FLT inhibitor known as FF-10101 was designed, which would form covalent bonds with the C695 residues of FLT3. The creation of covalent bonds by FF-10101 enables the selective and irreversible inhibition of FLT3 in either the active or the inactive form [111]. Furthermore, the unique binding method of FF-10101 exerts wide inhibitory action against various FLT3 mutations, including F691L. Currently, phase 1/2 trials are underway to evaluate its safety, tolerability, pharmacokinetics, and efficacy against recurrent refractory AML (NCT03194685). In addition, several agents that may overcome or prevent resistance are currently under investigation. A pan-PIM/FLT3 inhibitor SEL24 [112], a type II FLT3 inhibitor MZH29 [113], a MERTK/FLT3 inhibitor MRX-2843 [114], a BCR-ABL inhibitor ponatinib [115], and a multiple tyrosine kinase inhibitor cabozantinib [116] have exhibited anti-tumor activity in cases with FLT3-TKD, including those with the F691 pointmutation.

6.2. Combination with Different Class Agents

Existing FLT3 inhibitors are now being tested in combination with HMAs, standard chemotherapy, bortezomib (proteasome inhibitor), atezolizumab (anti-PD-L1 antibody), venetoclax (BCL-2 inhibitor), milademetan (MDM2 inhibitor) and homoharringtonine (STAT inhibitor). Ongoing trails of combination strategy are summarized in Table 3 Preclinically, FLT3 ligand-mediated resistance was attenuated by the dual inhibition of AKT/FLT3 in vivo [117]. The combination of the MEK and FLT3 inhibitors as well as the dual inhibition of MEK/FLT3 proved to be effective against resistance-conferring FLT3 mutations in in vivo and in vitro mutations [97,118]. The sensitization of FLT3 inhibitors can serve as an alternate strategy. Proteasome inhibitors, arsenic trioxide (ATO), and a CDK4/6 inhibitor palbociclib downregulated FLT3 molecules in FLT3-ITD AML cells by promoting cytotoxic autophagy, inhibiting the expression of FLT3 RNAs, and dysregulating the transcription of FLT3 and PIM1, respectively [119,120,121]. The inactivation of ATM or its downstream effector G6PD also induced synthetic lethality along with FLT3 inhibition by enhancing mitochondrial oxidative stress, which eventually resulted in tumor apoptosis [122].

6.3. Genetic Mutation Analysis

As described, the presence or absence of mutations in FLT3 has become an important determinant of the treatment methods in AML. Currently, a companion diagnostic tool LeukoStratCDx (Invivoscribe, Inc., San Diego, CA, USA) is widely used for the clinical use of FLT3 inhibitors in Japan, the United States, and Europe, among others. However, LeukoStratCDx is only able to detect D835 and I836 mutations and cannot detect any other FLT-TKD mutations, including F691L. Therefore, the instrument might incorrectly analyze the condition in patients with FLT3-TKD that is potentially treatable by FLT3 inhibitors. Although intensive chemotherapy has ensured substantial clinical benefit in AML patients, several patients eventually require targeted therapy, particularly young patients. In addition, CEBPA and NPM1, and recently TP53, ASXL1 and RUNX1, have been determined to be important markers prognosis [27,31,123], transplant eligibility, and treatment strategy. Even after FLT3-ITD/TKD becomes undetectable in remission, the expression of persistently mutated genes such as DNMT3A, TET2, SRSF2, and ASXL1 continues to be associated with high relapse rates and poor prognosis [124]. Although the negative prognostic impact of FLT3-ITD might be, at least partially, attenuated by upfront haploidentical stem cell transplantation (haplo-SCT) [125], FLT3 inhibitors remain one of the useful choices for treating the majority of FLT3-mutated AML patients, especially elderly and/or unfit people. To overcome resistance to FLT3 inhibitors, mutation analyses in patients with resistance to FLT3 inhibitors are required to identify the genetic abnormalities that contribute to drug-resistance and determine additional therapeutic targets. Genome-wide analysis using the CRISPR-Cas9 single-guide RNA (sgRNA) library, a vector-mediated technique for the knockdown of particular genes, revealed that the loss of SPRY3 and GSK3 confers resistance to quizartinib by inducing the reactivation of the FGF/RAS/ERK pathway and Wnt signaling [126]. Likewise, in addition to FLT3 mutations, it is necessary to comprehensively evaluate various genetic abnormalities; comprehensive mutation testing by next-generation sequencing (NGS) is expected to enable this. Accordingly, we analyzed the cancer-related genetic abnormalities (i.e., in an NGS panel) in patients with AML who were ineligible for intensive chemotherapy or developed recurrent/refractory cancer after initial therapy (Foundation One Heme; we planned HM-SCREEN-JAPAN, an observational study that analyzes and evaluates the relationship between prognosis by F1H). The primary goal of this project is the development of F1H and the promotion of targeted therapy for AML [127].

7. Conclusions and Future Perspectives

This paper described the principal mechanisms of resistance to FLT3 inhibition and the current investigations to overcome it. Secondary on-target mutations (i.e., FLT3-TKD) can be managed by choosing type I inhibitors such as gilteritinib that are consistently active against FLT3-TKD as well as FLT3-ITD, except for a “gatekeeper” F691L mutation. Covalently-coupling FF-10101 and other novel FLT3 inhibitors are now under investigation and have shown promising data on FLT3 F691L. Strategies for secondary off-target abnormalities and a part of primary resistance cannot be simple, regarding the diverse relating genomic abnormalities and complex patterns of clonal evolution. Nevertheless, some genetic abnormalities are/will be clinically targetable, expecting a synergistic anti-tumor effect with FLT3 inhibition. For example, several agents targeting BCL-2, MDM2 and STAT as well as conventional chemotherapy are being evaluated in combination with FLT3 inhibitors. Similarly, abnormal RAS and PIM1 pathways as well as metabolic modifications (e.g., G6PD inactivation) are subject to preclinical investigations. Recent studies have suggested the non-negligible importance of clone-evolutional patterns in terms of acquiring resistance, which possibly affects clinical strategy in managing FLT3-mutated AML. Simply, when you find two distinct targetable mutations and the corresponding agents are available (e.g., FLT3-ITD and IDH2 mutation), you can choose either one agent if both mutations are limited in a single leukemic clone, but if each mutations are found in different clones, it is worth considering combination or sequential therapy, if allowed. Routine and successive gene sequencing will help detecting additional targetable mutations and determining individual patterns of clone evolution, which would improve our clinical approaches along with the development of novel agents and combination strategies.
Several new agents such as FLT3 inhibitors can create overlapping treatment options, especially in the elderly, unfit AML patients as well as in relapse/refractory AML patients. A lot of clinical trials evaluating the efficacy of promising investigational drugs in AML are ongoing and more drugs will go to the market than ever before. Based on the resistant mechanisms during treatment, how to use these new agents properly is one of the issues with the treatment of AML. Physicians should select an optimal treatment depending on factors such as age, performance status, comorbidities, and genome profiling analysis upon new diagnoses and during treatment.

Author Contributions

M.E. and S.C. wrote the first draft and all authors revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This paper was supported by the National Cancer Research & Development expenses grant.

Conflicts of Interest

Y.M. received research funding from Ono and honoraria from Bristol-Myers Squibb, Novartis, and Pfizer. The other authors declare no conflict of interest.

References

  1. Rosnet, O.; Mattei, M.-G.; Marchetto, S.; Birnbaum, D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 1991, 9, 380–385. [Google Scholar] [CrossRef]
  2. Rosnet, O.; Schiff, C.; Pebusque, M.J.; Marchetto, S.; Tonnelle, C.; Toiron, Y.; Birg, F.; Birnbaum, D. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993, 82, 1110–1119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Lemmon, M.A.; Schlessinger, J. Cell Signaling by Receptor Tyrosine Kinases. Cell 2010, 141, 1117–1134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Small, D.; Levenstein, M.; Kim, E.; Carow, C.; Amin, S.; Rockwell, P.; Witte, L.; Burrow, C.; Ratajczak, M.Z.; Gewirtz, A.M. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA 1994, 91, 459–463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Hannum, C.; Culpepper, J.; Campbell, D.; McClanahan, T.; Zurawski, S.; Kastelein, R.; Bazan, J.F.; Hudak, S.; Wagner, J.; Mattson, J.; et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994, 368, 643–648. [Google Scholar] [CrossRef] [PubMed]
  6. Lyman, S.D.; James, L.; Bos, T.V.; De Vries, P.; Brasel, K.; Gliniak, B.; Hollingsworth, L.; Picha, K.S.; McKenna, H.J.; Splett, R.R.; et al. Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells. Cell 1993, 75, 1157–1167. [Google Scholar] [CrossRef]
  7. Hayakawa, F.; Towatari, M.; Kiyoi, H.; Tanimoto, M.; Kitamura, T.; Saito, H.; Naoe, T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000, 19, 624–631. [Google Scholar] [CrossRef] [Green Version]
  8. Mizuki, M.; Fenski, R.; Halfter, H.; Matsumura, I.; Schmidt, R.; Müller, C.; Grüning, W.; Kratz-Albers, K.; Serve, S.; Steur, C.; et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000, 96, 3907–3914. [Google Scholar] [CrossRef]
  9. Meshinchi, S.; Appelbaum, F.R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin. Cancer Res. 2009, 15, 4263–4269. [Google Scholar] [CrossRef] [Green Version]
  10. Stirewalt, D.L.; Radich, J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 2003, 3, 650–665. [Google Scholar] [CrossRef]
  11. Drexler, H.G.; Meyer, C.; Quentmeier, H. Effects of FLT3 Ligand on Proliferation and Survival of Myeloid Leukemia Cells. Leuk. Lymphoma 1999, 33, 83–91. [Google Scholar] [CrossRef] [PubMed]
  12. Nakao, M.; Yokota, S.; Iwai, T.; Kaneko, H.; Horiike, S.; Kashima, K.; Sonoda, Y.; Fujimoto, T.; Misawa, S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10, 1911–1918. [Google Scholar] [PubMed]
  13. Yamamoto, Y. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97, 2434–2439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Kiyoi, H.; Naoe, T. Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with FLT3 Mutation. Int. J. Hematol. 2006, 83, 301–308. [Google Scholar] [CrossRef]
  15. Kihara, R.; Nagata, Y.; Kiyoi, H.; Kato, T.; Yamamoto, E.; Suzuki, K.; Chen, F.; Asou, N.; Ohtake, S.; Miyawaki, S.; et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 2014, 28, 1586–1595. [Google Scholar] [CrossRef]
  16. Ley, T.J.; Miller, C.A.; Ding, L.; Raphael, B.J.; Mungall, A.J.; Robertson, A.G.; Hoadley, K.A.; Triche, T.J.; Laird, P.W.; Baty, J.D.; et al. The Cancer Genome Atlas Research Network; Cancer Genome Atlas Research Network; Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med. 2013, 368, 2059–2074. [Google Scholar] [CrossRef] [Green Version]
  17. Janke, H.; Pastore, F.; Schumacher, D.; Herold, T.; Hopfner, K.-P.; Schneider, S.; Berdel, W.E.; Buchner, T.; Woermann, B.J.; Subklewe, M.; et al. Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia. PLoS ONE 2014, 9, e89560. [Google Scholar] [CrossRef] [Green Version]
  18. Okada, K.; Nogami, A.; Ishida, S.; Akiyama, H.; Chen, C.; Umezawa, Y.; Miura, O. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. Oncotarget 2017, 9, 8870–8886. [Google Scholar] [CrossRef]
  19. Solovey, M.; Wang, Y.; Michel, C.; Metzeler, K.H.; Herold, T.; Göthert, J.R.; Ellenrieder, V.; Hessmann, E.; Gattenlöhner, S.; Neubauer, A.; et al. Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML. J. Hematol. Oncol. 2019, 12, 72. [Google Scholar] [CrossRef]
  20. Sun, Y.-M.; Wang, W.-T.; Zeng, Z.-C.; Chen, T.-Q.; Han, C.; Pan, Q.; Huang, W.; Fang, K.; Sun, L.-Y.; Zhou, Y.-F.; et al. circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression. Blood 2019, 134, 1533–1546. [Google Scholar] [CrossRef] [Green Version]
  21. Zhang, Y.; Askenazi, M.; Jiang, J.; Luckey, C.J.; Griffin, J.D.; Marto, J.A. A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia. Mol. Cell. Proteom. 2009, 9, 780–790. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Klingmüller, U.; Lorenz, U.; Cantley, L.C.; Neel, B.G.; Lodish, H.F. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995, 80, 729–738. [Google Scholar] [CrossRef] [Green Version]
  23. Grundler, R.; Miething, C.; Thiede, C.; Peschel, C.; Duyster, J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005, 105, 4792–4799. [Google Scholar] [CrossRef] [PubMed]
  24. Bailey, E.; Li, L.; Duffield, A.S.; Ma, H.S.; Huso, D.L.; Small, N. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc. Natl. Acad. Sci. USA 2013, 110, 21113–21118. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Bagrintseva, K.; Geisenhof, S.; Kern, R.; Eichenlaub, S.; Reindl, C.; Ellwart, J.W.; Hiddemann, W.; Spiekermann, K. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood 2005, 105, 3679–3685. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Kiyoi, H. FLT3 Inhibitors: Recent advances and problems for clinical application. Nagoya J. Med. Sci. 2015, 77, 7–17. [Google Scholar]
  27. Döhner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F.R.; Büchner, T.; Dombret, H.; Ebert, B.L.; Fenaux, P.; Larson, R.A.; et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017, 129, 424–447. [Google Scholar] [CrossRef] [Green Version]
  28. Ghiaur, G.; Levis, M.J. Mechanisms of Resistance to FLT3 Inhibitors and the Role of the Bone Marrow Microenvironment. Hematol. Clin. N. Am. 2017, 31, 681–692. [Google Scholar] [CrossRef]
  29. Zhou, J.; Chng, W.-J. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World J. Clin. Oncol. 2018, 9, 90–97. [Google Scholar] [CrossRef]
  30. Daver, N.; Schlenk, R.F.; Russell, N.H.; Levis, M.J. Targeting FLT3 mutations in AML: Review of current knowledge and evidence. Leukemia 2019, 33, 299–312. [Google Scholar] [CrossRef] [Green Version]
  31. Port, M.; Böttcher, M.; Thol, F.; Ganser, A.; Schlenk, R.; Wasem, J.; Neumann, A.; Pouryamout, L. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: A systematic review and meta-analysis. Ann. Hematol. 2014, 93, 1279–1286. [Google Scholar] [CrossRef] [PubMed]
  32. Thiede, C.; Steudel, C.; Mohr, B.; Schaich, M.; Schäkel, U.; Platzbecker, U.; Wermke, M.; Bornhäuser, M.; Ritter, M.; Neubauer, A.; et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99, 4326–4335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Schlenk, R.F.; Kayser, S.; Bullinger, L.; Kobbe, G.; Casper, J.; Ringhoffer, M.; Held, G.; Brossart, P.; Lübbert, M.; Salih, H.R.; et al. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation. Blood 2014, 124, 3441–3449. [Google Scholar] [CrossRef] [Green Version]
  34. Yalniz, F.F.; Dalle, I.A.; Kantarjian, H.M.; Borthakur, G.; Kadia, T.M.; Patel, K.; Loghavi, S.; Garcia-Manero, G.; Sasaki, K.; Daver, N.; et al. Prognostic significance of baselineFLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am. J. Hematol. 2019, 94, 984–991. [Google Scholar] [CrossRef]
  35. Pratcorona, M.; Brunet, S.; Nomdedéu, J.F.; Ribera, J.; Tormo, M.; Duarte, R.; Escoda, L.; Guàrdia, R.; De Llano, M.P.Q.; Salamero, O.; et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: Relevance to post-remission therapy. Blood 2013, 121, 2734–2738. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Linch, D.C.; Hills, R.K.; Burnett, A.K.; Khwaja, A.; Gale, R.E. Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood 2014, 124, 273–276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Versluis, J.; Devillier, R.; Van Putten, W.L.J.; Manz, M.G.; Vekemans, M.-C.; Legdeur, M.-C.; Passweg, J.R.; Maertens, J.; Kuball, J.; Biemond, B.J.; et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia 2016, 31, 26–33. [Google Scholar] [CrossRef]
  38. Sakaguchi, M.; Yamaguchi, H.; Najima, Y.; Usuki, K.; Ueki, T.; Oh, I.; Mori, S.; Kawata, E.; Uoshima, N.; Kobayashi, Y.; et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv. 2018, 2, 2744–2754. [Google Scholar] [CrossRef] [Green Version]
  39. Bacher, U.; Haferlach, C.; Kern, W.; Haferlach, T.; Schnittger, S. Prognostic relevance of FLT3-TKD mutations in AML: The combination matters—An analysis of 3082 patients. Blood 2008, 111, 2527–2537. [Google Scholar] [CrossRef]
  40. Zhang, H.; Savage, S.; Reister-Schultz, A.; Bottomly, D.; White, L.; Segerdell, E.; Wilmot, B.; McWeeney, S.K.; Eide, C.A.; Nechiporuk, T.; et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat. Commun. 2019, 10, 244. [Google Scholar] [CrossRef]
  41. Kelly, L.M.; Yu, J.-C.; Boulton, C.L.; Apatira, M.; Li, J.; Sullivan, C.M.; Williams, I.; Amaral, S.M.; Curley, D.P.; Duclos, N.; et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002, 1, 421–432. [Google Scholar] [CrossRef] [Green Version]
  42. Smith, B.D.; Levis, M.; Beran, M.; Giles, F.; Kantarjian, H.; Berg, K.; Murphy, K.M.; Dauses, T.; Allebach, J.; Small, D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004, 103, 3669–3676. [Google Scholar] [CrossRef] [PubMed]
  43. Stone, R.M.; DeAngelo, D.J.; Klimek, V.; Galinsky, I.; Estey, E.; Nimer, S.D.; Grandin, W.; Lebwohl, D.; Wang, Y.; Cohen, P.; et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105, 54–60. [Google Scholar] [CrossRef] [PubMed]
  44. Fiedler, W.; Serve, H.; Döhner, H.; Schwittay, M.; Ottmann, O.G.; O’Farrell, A.-M.; Bello, C.L.; Allred, R.; Manning, W.C.; Cherrington, J.M.; et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005, 105, 986–993. [Google Scholar] [CrossRef] [PubMed]
  45. Ravandi, F.; Cortes, J.E.; Jones, D.; Faderl, S.; Garcia-Manero, G.; Konopleva, M.Y.; O’Brien, S.; Estrov, Z.; Borthakur, G.; Thomas, D.; et al. Phase I/II Study of Combination Therapy with Sorafenib, Idarubicin, and Cytarabine in Younger Patients with Acute Myeloid Leukemia. J. Clin. Oncol. 2010, 28, 1856–1862. [Google Scholar] [CrossRef] [PubMed]
  46. Mori, M.; Kaneko, N.; Ueno, Y.; Yamada, M.; Tanaka, R.; Saito, R.; Shimada, I.; Mori, K.; Kuromitsu, S. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Investig. New Drugs 2017, 35, 556–565. [Google Scholar] [CrossRef] [Green Version]
  47. Lee, L.Y.; Hernandez, D.; Rajkhowa, T.; Smith, S.C.; Raman, J.; Nguyen, B.; Small, N.; Levis, M. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood 2017, 129, 257–260. [Google Scholar] [CrossRef] [Green Version]
  48. Zarrinkar, P.P.; Gunawardane, R.N.; Cramer, M.D.; Gardner, M.F.; Brigham, D.; Belli, B.; Karaman, M.W.; Pratz, K.W.; Pallares, G.; Chao, Q.; et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114, 2984–2992. [Google Scholar] [CrossRef]
  49. Galanis, A.; Ma, H.; Rajkhowa, T.; Ramachandran, A.; Small, N.; Cortes, J.; Levis, M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood 2014, 123, 94–100. [Google Scholar] [CrossRef] [Green Version]
  50. Smith, C.C.; Lasater, E.A.; Lin, K.C.; Wang, Q.; McCreery, M.Q.; Stewart, W.K.; Damon, L.E.; Perl, A.E.; Jeschke, G.; Sugita, M.; et al. Crenolanib is a selective type I pan-FLT3 inhibitor. Proc. Natl. Acad. Sci. USA 2014, 111, 5319–5324. [Google Scholar] [CrossRef] [Green Version]
  51. Angiolini, M. Targeting the DFG-in kinase conformation: A new trend emerging from a patent analysis. Future Med. Chem. 2011, 3, 309–337. [Google Scholar] [CrossRef] [PubMed]
  52. Ke, Y.-Y.; Singh, V.K.; Coumar, M.S.; Hsu, Y.C.; Wang, W.-C.; Song, J.-S.; Chen, C.-H.; Lin, W.-H.; Wu, S.-H.; Hsu, J.T.A.; et al. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci. Rep. 2015, 5, 11702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Bhullar, K.S.; Lagarón, N.O.; McGowan, E.M.; Parmar, I.; Jha, A.; Hubbard, B.P.; Rupasinghe, H.P.V. Kinase-targeted cancer therapies: Progress, challenges and future directions. Mol. Cancer 2018, 17, 1–20. [Google Scholar] [CrossRef] [PubMed]
  54. Kiyoi, H.; Kawashima, N.; Ishikawa, Y. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2019, 111, 312–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Smith, C.C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N.P. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 2015, 29, 2390–2392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Williams, A.B.; Nguyen, B.; Li, L.; Brown, P.; Levis, M.; Leahy, D.; Small, N. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia 2012, 27, 48–55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Cools, J. Prediction of Resistance to Small Molecule FLT3 Inhibitors: Implications for Molecularly Targeted Therapy of Acute Leukemia. Cancer Res. 2004, 64, 6385–6389. [Google Scholar] [CrossRef] [Green Version]
  58. McMahon, C.M.; Canaani, J.; Rea, B.; McMahon, C.M.; Canaani, J.; Rea, B.; Sargent, R.L.; Morrissette, J.J.; Lieberman, D.B.; Watt, C.; et al. Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia. Blood 2017, 130 (Suppl. 1), 295. [Google Scholar] [CrossRef]
  59. Staudt, D.; Murray, H.C.; McLachlan, T.; Alvaro, F.; Enjeti, A.K.; Verrills, N.M.; Dun, M.D. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. Int. J. Mol. Sci. 2018, 19, 3198. [Google Scholar] [CrossRef] [Green Version]
  60. Eid, S.; Turk, S.; Volkamer, A.; Rippmann, F.; Fulle, S. KinMap: A web-based tool for interactive navigation through human kinome data. BMC Bioinform. 2017, 18, 16. [Google Scholar] [CrossRef] [Green Version]
  61. Klaeger, S.; Heinzlmeir, S.; Wilhelm, M.; Polzer, H.; Vick, B.; Koenig, P.-A.; Reinecke, M.; Ruprecht, B.; Wiechmann, S.; Meng, C.; et al. The target landscape of clinical kinase drugs. Science 2017, 358, 4368. [Google Scholar] [CrossRef] [Green Version]
  62. Karaman, M.W.; Herrgard, S.; Treiber, D.K.; Gallant, P.; Atteridge, C.E.; Campbell, B.T.; Chan, K.W.; Ciceri, P.; Davis, M.I.; Edeen, P.T.; et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26, 127–132. [Google Scholar] [CrossRef] [PubMed]
  63. Weisberg, E.; Puissant, A.; Stone, R.; Sattler, M.; Buhrlage, S.J.; Yang, J.; Manley, P.W.; Meng, C.; Buonopane, M.; Daley, J.F.; et al. Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget 2017, 8, 52026–52044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. O’Farrell, A.-M.; Abrams, T.J.; Yuen, H.A.; Ngai, T.J.; Louie, S.G.; Yee, K.W.H.; Wong, L.M.; Hong, W.; Lee, L.B.; Town, A.; et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101, 3597–3605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Levis, M.J.; Allebach, J.; Tse, K.-F.; Zheng, R.; Baldwin, B.R.; Smith, B.D.; Jones-Bolin, S.; Ruggeri, B.; Dionne, C.; Small, N. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002, 99, 3885–3891. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Mori, S.; Cortes, J.; Kantarjian, H.; Zhang, W.; Andreef, M.; Ravandi, F. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk. Lymphoma 2008, 49, 2246–2255. [Google Scholar] [CrossRef] [Green Version]
  67. Schittenhelm, M.M.; Kampa, K.M.; Yee, K.W.H.; Heinrich, M.C. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009, 8, 2621–2630. [Google Scholar] [CrossRef]
  68. Aikawa, T.; Togashi, N.; Iwanaga, K.; Okada, H.; Nishiya, Y.; Inoue, S.; Levis, M.J.; Isoyama, T. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. Oncotarget 2020, 11, 943–955. [Google Scholar] [CrossRef]
  69. Nguyen, B.; Williams, A.B.; Young, D.J.; Ma, H.; Li, L.; Levis, M.; Brown, P.; Small, N. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. Oncotarget 2017, 8, 10931–10944. [Google Scholar] [CrossRef] [Green Version]
  70. Barry, E.V.; Clark, J.J.; Cools, J.; Roesel, J.; Gilliland, D.G. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. Blood 2007, 110, 4476–4479. [Google Scholar] [CrossRef] [Green Version]
  71. Yee, K.W.H.; Schittenhelm, M.; O’Farrell, A.-M.; Town, A.R.; McGreevey, L.; Bainbridge, T.; Cherrington, J.M.; Heinrich, M.C. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells. Blood 2004, 104, 4202–4209. [Google Scholar] [CrossRef] [PubMed]
  72. Schittenhelm, M.M.; Heinrich, M.C.; Akmut, F.; Döhner, H.; Döhner, K.; Schittenhelm, M.M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol. Cancer 2013, 12, 19. [Google Scholar] [CrossRef] [PubMed]
  73. Stone, R.M.; Mandrekar, S.J.; Sanford, B.L.; Laumann, K.; Geyer, S.; Bloomfield, C.D.; Thiede, C.; Prior, T.W.; Döhner, K.; Marcucci, G.; et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl. J. Med. 2017, 377, 454–464. [Google Scholar] [CrossRef] [PubMed]
  74. Schlenk, R.F.; Weber, D.; Fiedler, W.; Salih, H.R.; Wulf, G.; Salwender, H.; Schroeder, T.; Kindler, T.; Lübbert, M.; Wolf, D.; et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 2019, 133, 840–851. [Google Scholar] [CrossRef]
  75. Perl, A.E.; Martinelli, G.; Cortes, J.E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M.R.; Larson, R.A.; Ustun, C.; et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N. Engl. J. Med. 2019, 381, 1728–1740. [Google Scholar] [CrossRef]
  76. Cortes, J.; Khaled, S.; Martinelli, G.; Perl, A.E.; Ganguly, S.; Russell, N.; Krämer, A.; Dombret, H.; Hogge, D.; Jonas, B.A.; et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019, 20, 984–997. [Google Scholar] [CrossRef]
  77. Altman, J.K.; Foran, J.M.; Pratz, K.W.; Trone, D.; Cortes, J.E.; Tallman, M.S. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. Am. J. Hematol. 2017, 93, 213–221. [Google Scholar] [CrossRef]
  78. Röllig, C.; Serve, H.; Hüttmann, A.; Noppeney, R.; Mueller-Tidow, C.; Krug, U.; Baldus, C.D.; Brandts, C.H.; Kunzmann, V.; Einsele, H.; et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015, 16, 1691–1699. [Google Scholar] [CrossRef]
  79. Uy, G.L.; Mandrekar, S.J.; Laumann, K.; Marcucci, G.; Zhao, W.; Levis, M.J.; Klepin, H.D.; Baer, M.R.; Powell, B.L.; Westervelt, P.; et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017, 1, 331–340. [Google Scholar] [CrossRef]
  80. Ohanian, M.; Garcia-Manero, G.; Levis, M.J.; Jabbour, E.; Daver, N.; Borthakur, G.; Kadia, T.; Pierce, S.; Burger, J.; Richie, M.A.; et al. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am. J. Hematol. 2018, 93, 1136–1141. [Google Scholar] [CrossRef] [Green Version]
  81. Sasaki, K.; Kantarjian, H.M.; Kadia, T.M.; Patel, K.; Loghavi, S.; Garcia-Manero, G.; Jabbour, E.J.; Dinardo, C.D.; Pemmaraju, N.; Daver, N.; et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation–positive acute myeloid leukemia. Cancer 2019, 125, 3755–3766. [Google Scholar] [CrossRef]
  82. Muppidi, M.R.; Portwood, S.; Griffiths, E.A.; Thompson, J.E.; Ford, L.A.; Freyer, C.W.; Wetzler, M.; Wang, E.S. Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. Clin. Lymphoma Myeloma Leuk. 2015, 15, S73–S79. [Google Scholar] [CrossRef]
  83. Ravandi, F.; Alattar, M.L.; Grunwald, M.R.; Rudek, M.A.; Rajkhowa, T.; Richie, M.A.; Pierce, S.; Daver, N.; Garcia-Manero, G.; Faderl, S.; et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood 2013, 121, 4655–4662. [Google Scholar] [CrossRef]
  84. Bazarbachi, A.; Labopin, M.; Battipaglia, G.; Djabali, A.; Passweg, J.; Socié, G.; Forcade, E.; Blaise, D.; Chevallier, P.; Orvain, C.; et al. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: A report of the EBMT Acute Leukemia Working Party. Haematologica 2019, 104, e398–e401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  85. Wang, E.S.; Stone, R.M.; Tallman, M.S.; Walter, R.B.; Eckardt, J.R.; Collins, R. Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). Blood 2016, 128, 1071. [Google Scholar] [CrossRef]
  86. Iyer, S.P.; Jethava, Y.; Karanes, C.; Eckardt, J.R.; Collins, R. Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML. Blood 2016, 128, 3983. [Google Scholar] [CrossRef]
  87. Ohanian, M.; Kantarjian, H.M.; Borthakur, G.; Kadia, T.M.; Konopleva, M.; Garcia-Manero, G.; Estrov, Z.; Ferrajoli, A.; Takahashi, K.; Jabbour, E.J.; et al. Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML. Blood 2016, 128, 2744. [Google Scholar] [CrossRef]
  88. Levis, M.J.; Ravandi, F.; Wang, E.S.; Baer, M.R.; Perl, A.; Coutre, S.; Erba, H.; Stuart, R.K.; Baccarani, M.; Cripe, L.D.; et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011, 117, 3294–3301. [Google Scholar] [CrossRef]
  89. Knapper, S.; Russell, N.; Gilkes, A.; Hills, R.K.; Gale, R.E.; Cavenagh, J.D.; Jones, G.; Kjeldsen, L.; Grunwald, M.R.; Thomas, I.; et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 2017, 129, 1143–1154. [Google Scholar] [CrossRef]
  90. Sato, T.; Yang, X.; Knapper, S.; White, P.; Smith, B.D.; Galkin, S.; Small, D.; Burnett, A.; Levis, M.J. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011, 117, 3286–3293. [Google Scholar] [CrossRef] [Green Version]
  91. Chen, F.; Ishikawa, Y.; Akashi, A.; Naoe, T.; Kiyoi, H. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget 2016, 7, 47018–47032. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Traer, E.; Martinez, J.; Javidi-Sharifi, N.; Agarwal, A.; Dunlap, J.; English, I.; Kovacsovics, T.; Tyner, J.W.; Wong, M.; Druker, B.J. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res. 2016, 76, 6471–6482. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Jacobi, A.; Thieme, S.; Lehmann, R.; Ugarte, F.; Malech, H.L.; Koch, S.; Thiede, C.; Müller, K.; Bornhäuser, M.; Ryser, M.; et al. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts. Exp. Hematol. 2009, 38, 180–190. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. Zeng, Z.; Shi, Y.X.; Samudio, I.J.; Wang, R.-Y.; Ling, X.; Frolova, O.; Levis, M.; Rubin, J.B.; Negrin, R.R.; Estey, E.H.; et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113, 6215–6224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Chang, Y.-T.; Hernandez, D.; Alonso, S.; Gao, M.; Su, M.; Ghiaur, G.; Levis, M.J.; Jones, R.J. Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors. Blood Adv. 2019, 3, 908–916. [Google Scholar] [CrossRef] [PubMed]
  96. Smith, C.C.; Wang, Q.; Chin, C.-S.; Salerno, S.; Damon, L.E.; Levis, M.J.; Perl, A.E.; Travers, K.J.; Wang, S.; Hunt, J.P.; et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485, 260–263. [Google Scholar] [CrossRef] [Green Version]
  97. McMahon, C.M.; Ferng, T.; Canaani, J.; Wang, E.S.; Morrissette, J.J.; Eastburn, D.J.; Pellegrino, M.; Durruthy-Durruthy, R.; Watt, C.D.; Asthana, S.; et al. Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2019, 9, 1050–1063. [Google Scholar] [CrossRef]
  98. Piloto, O.; Wright, M.; Brown, P.; Kim, K.-T.; Levis, M.; Small, D. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007, 109, 1643–1652. [Google Scholar] [CrossRef] [Green Version]
  99. Park, I.-K.; Mundy-Bosse, B.; Whitman, S.P.; Zhang, X.; Warner, S.L.; Bearss, D.; Blum, W.; Marcucci, G.; Caligiuri, M.A. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia 2015, 29, 2382–2389. [Google Scholar] [CrossRef]
  100. Dumas, P.-Y.; Naudin, C.; Martin-Lannerée, S.; Izac, B.; Casetti, L.; Mansier, O.; Rousseau, B.; Artus, A.; Dufossée, M.; Giese, A.; et al. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL. Haematologica 2019, 104, 2017–2027. [Google Scholar] [CrossRef] [Green Version]
  101. Dinardo, C.D.; Stein, E.M.; De Botton, S.; Roboz, G.J.; Altman, J.K.; Mims, A.S.; Swords, R.; Collins, R.H.; Mannis, G.N.; Pollyea, D.A.; et al. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML. N. Engl. J. Med. 2018, 378, 2386–2398. [Google Scholar] [CrossRef] [PubMed]
  102. Stein, E.M.; Dinardo, C.D.; Fathi, A.T.; Pollyea, D.A.; Stone, R.M.; Altman, J.K.; Roboz, G.J.; Patel, M.R.; Collins, R.; Flinn, I.W.; et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood 2019, 133, 676–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Stein, E.M.; Dinardo, C.D.; Pollyea, D.A.; Fathi, A.T.; Roboz, G.J.; Altman, J.K.; Stone, R.M.; DeAngelo, D.J.; Levine, R.L.; Flinn, I.W.; et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017, 130, 722–731. [Google Scholar] [CrossRef] [PubMed]
  104. Lindblad, O.; Cordero, E.; Puissant, A.; Macaulay, L.; Ramos, A.; Kabir, N.N.; Sun, J.; Vallon-Christersson, J.; Haraldsson, K.; Hemann, M.T.; et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene 2016, 35, 5119–5131. [Google Scholar] [CrossRef]
  105. Tursynbay, Y.; Zhang, J.; Li, Z.; Tokay, T.; Zhumadilov, Z.; Wu, D.; Xie, Y. Pim-1 kinase as cancer drug target: An update. Biomed. Rep. 2015, 4, 140–146. [Google Scholar] [CrossRef] [Green Version]
  106. Kim, K.-T.; Baird, K.; Ahn, J.-Y.; Meltzer, P.; Lilly, M.; Levis, M.J.; Small, N. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005, 105, 1759–1767. [Google Scholar] [CrossRef] [Green Version]
  107. Green, A.S.; Maciel, T.; Hospital, M.-A.; Yin, C.; Mazed, F.; Townsend, E.C.; Pilorge, S.; Lambert, M.; Paubelle, E.; Jacquel, A.; et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci. Adv. 2015, 1, e1500221. [Google Scholar] [CrossRef] [Green Version]
  108. Kohl, T.M.; Hellinger, C.; Ahmed, F.; Buske, C.; Hiddemann, W.; Bohlander, S.K.; Spiekermann, K. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007, 21, 1763–1772. [Google Scholar] [CrossRef]
  109. Breitenbuecher, F.; Markova, B.; Kasper, S.; Carius, B.; Stauder, T.; Böhmer, F.D.; Masson, K.; Rönnstrand, L.; Huber, C.; Kindler, T.; et al. A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood 2009, 113, 4063–4073. [Google Scholar] [CrossRef] [Green Version]
  110. Yoshimoto, G.; Miyamoto, T.; Jabbarzadeh-Tabrizi, S.; Iino, T.; Rocnik, J.L.; Kikushige, Y.; Mori, Y.; Shima, T.; Iwasaki, H.; Takenaka, K.; et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation. Blood 2009, 114, 5034–5043. [Google Scholar] [CrossRef] [Green Version]
  111. Yamaura, T.; Nakatani, T.; Uda, K.; Ogura, H.; Shin, W.; Kurokawa, N.; Saito, K.; Fujikawa, N.; Date, T.; Takasaki, M.; et al. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood 2018, 131, 426–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Czardybon, W.; Windak, R.; Gołas, A.; Gałezowski, M.; Sabiniarz, A.; Dolata, I.; Salwińska, M.; Guzik, P.; Zawadzka, M.; Gabor-Worwa, E.; et al. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget 2018, 9, 16917–16931. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Xu, B.; Zhao, Y.; Wang, X.; Gong, P.; Ge, W. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Leukemia 2016, 31, 913–921. [Google Scholar] [CrossRef] [PubMed]
  114. Minson, K.A.; Smith, C.C.; DeRyckere, D.; Libbrecht, C.; Sherick, A.L.; Huey, M.G.; Lasater, E.A.; Kirkpatrick, G.D.; Stashko, M.A.; Zhang, W.; et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight 2016, 1. [Google Scholar] [CrossRef]
  115. Zirm, E.; Spies-Weisshart, B.; Heidel, F.H.; Schnetzke, U.; Böhmer, F.-D.; Hochhaus, A.; Fischer, T.; Scholl, S. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br. J. Haematol. 2012, 157, 483–492. [Google Scholar] [CrossRef]
  116. Sung, L.; Blonquist, T.M.; Hernandez, D.; Amrein, P.C.; Ballen, K.K.; McMasters, M.; Avigan, D.; Joyce, R.; Logan, E.K.; Hobbs, G.S.; et al. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer 2017, 124, 306–314. [Google Scholar] [CrossRef] [Green Version]
  117. Wang, A.; Wu, H.; Chen, C.; Hu, C.; Qi, Z.; Wang, W.; Yu, K.; Liu, X.; Zou, F.; Zhao, Z.; et al. Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. Oncotarget 2016, 7, 29131–29142. [Google Scholar] [CrossRef]
  118. Zhang, W.; Borthakur, G.; Gao, C.; Chen, Y.; Mu, H.; Ruvolo, V.R.; Nomoto, K.; Zhao, N.; Konopleva, M.; Andreeff, M. The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations. Cancer Res. 2016, 76, 1528–1537. [Google Scholar] [CrossRef] [Green Version]
  119. Larrue, C.; Saland, E.; Boutzen, H.; Vergez, F.; David, M.; Joffre, C.; Hospital, M.-A.; Tamburini, J.; Delabesse, E.; Manenti, S.; et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells. Blood 2016, 127, 882–892. [Google Scholar] [CrossRef] [Green Version]
  120. Nagai, K.; Hou, L.; Li, L.; Nguyen, B.; Seale, T.; Shirley, C.; Ma, H.; Levis, M.; Ghiaur, G.; Duffield, A.; et al. Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3. Oncotarget 2018, 9, 32885–32899. [Google Scholar] [CrossRef] [Green Version]
  121. Uras, I.Z.; Walter, G.J.; Scheicher, R.; Bellutti, F.; Prchal-Murphy, M.; Tigan, A.S.; Valent, P.; Heidel, F.H.; Kubicek, S.; Scholl, C.; et al. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood 2016, 127, 2890–2902. [Google Scholar] [CrossRef] [Green Version]
  122. Gregory, M.; D’Alessandro, A.; Alvarez-Calderon, F.; Kim, J.; Nemkov, T.; Adane, B.; Rozhok, A.I.; Kumar, A.; Kumar, V.; Pollyea, D.A.; et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 2016, 113, E6669–E6678. [Google Scholar] [CrossRef] [Green Version]
  123. Dickson, G.J.; Bustraan, S.; Hills, R.K.; Ali, A.; Goldstone, A.H.; Burnett, A.K.; Linch, D.C.; Gale, R.E. The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia. Br. J. Haematol. 2015, 172, 573–580. [Google Scholar] [CrossRef] [Green Version]
  124. Rothenberg-Thurley, M.; Amler, S.; Goerlich, D.; Kohnke, T.; Konstandin, N.P.; Schneider, S.; Sauerland, M.C.; Herold, T.; Hubmann, M.; Ksienzyk, B.; et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia 2018, 32, 1598–1608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Canaani, J.; Labopin, M.; Huang, X.-J.; Arcese, W.; Ciceri, F.; Blaise, D.; Irrera, G.; Corral, L.L.; Bruno, B.; Santarone, S.; et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am. J. Hematol. 2018, 93, 736–744. [Google Scholar] [CrossRef] [Green Version]
  126. Hou, P.; Wu, C.; Wang, Y.; Qi, R.; Bhavanasi, D.; Zuo, Z.; Dos Santos, C.; Chen, S.; Chen, Y.; Zheng, H.; et al. A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. Cancer Res. 2017, 77, 4402–4413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  127. Miyamoto, K.; Minami, Y. Precision medicine and novel molecular target therapies in acute myeloid leukemia: The background of hematologic malignancies (HM)-SCREEN-Japan 01. Int. J. Clin. Oncol. 2019, 24, 893–898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Biomedicines 08 00245 g001 550
Figure 1. Schematic mechanisms of primary resistance to FLT3 inhibitors. (1) Wild-type FLT3s are a little sensitive to FLT3 inhibitors and allow downstream signaling by binding with FLT3 ligands. (2) FGF2 secreted from bone marrow stromal cells activates FGFR1 on leukemic cells which leads to MAPK activation. (3) Cell adhesion to the microenvironment may also help leukemic proliferation. Antagonizing CXCR4 that binds to CXCL12 on osteoblasts resulted in attenuated leukemia progression. (4) Upregulating CYP3A4 leads to the rapid inactivation of FLT3 inhibitors.
Figure 1. Schematic mechanisms of primary resistance to FLT3 inhibitors. (1) Wild-type FLT3s are a little sensitive to FLT3 inhibitors and allow downstream signaling by binding with FLT3 ligands. (2) FGF2 secreted from bone marrow stromal cells activates FGFR1 on leukemic cells which leads to MAPK activation. (3) Cell adhesion to the microenvironment may also help leukemic proliferation. Antagonizing CXCR4 that binds to CXCL12 on osteoblasts resulted in attenuated leukemia progression. (4) Upregulating CYP3A4 leads to the rapid inactivation of FLT3 inhibitors.
Biomedicines 08 00245 g001
Biomedicines 08 00245 g002 550
Figure 2. Additional FLT3 tyrosine kinase domain mutations responsible for secondary on-target resistance. These mutations keep the TK domain in active FDG-in form, not allowing the type II inhibitors to bind there. Mutations in a “gate-keeping” residue F691 shows the universal resistance to both type I and II inhibitors.
Figure 2. Additional FLT3 tyrosine kinase domain mutations responsible for secondary on-target resistance. These mutations keep the TK domain in active FDG-in form, not allowing the type II inhibitors to bind there. Mutations in a “gate-keeping” residue F691 shows the universal resistance to both type I and II inhibitors.
Biomedicines 08 00245 g002
Biomedicines 08 00245 g003 550
Figure 3. Schematic description of genetic abnormalities (mutations or upregulation) associated with secondary off-target resistance to FLT3 inhibitors. Mutations involved in the RAS/MAPK pathway were reported. NRAS mutation is the most common among them. Axl-1, coded by the AXL gene, is a receptor tyrosine kinase that leads to the activation of RAS/MARK and PI3K/Akt/mTOR pathway. The upregulation of the AXL gene was observed in midostaurin-resistant AML cell lines. Pim-1 is part of the downstream signaling of STAT5, contributing cell survival and proliferation as well as cell migration. A lestaurtinib-resistant AML cell line showed the overexpression of Pim-1. Other gene mutations commonly seen in AML regardless of FLT3 status were also detected. Although a direct relationship with FLT3 signaling was not suggested, these mutations have an essential role in maintaining leukemic clones by modulating epigenetic/transcriptional regulations (e.g., ASXL1, TET2, DNMT3A and STAG2), altering the metabolism of the citrate acid cycle (e.g., IDH1 and IDH2) and preventing apoptosis (e.g., TP53).
Figure 3. Schematic description of genetic abnormalities (mutations or upregulation) associated with secondary off-target resistance to FLT3 inhibitors. Mutations involved in the RAS/MAPK pathway were reported. NRAS mutation is the most common among them. Axl-1, coded by the AXL gene, is a receptor tyrosine kinase that leads to the activation of RAS/MARK and PI3K/Akt/mTOR pathway. The upregulation of the AXL gene was observed in midostaurin-resistant AML cell lines. Pim-1 is part of the downstream signaling of STAT5, contributing cell survival and proliferation as well as cell migration. A lestaurtinib-resistant AML cell line showed the overexpression of Pim-1. Other gene mutations commonly seen in AML regardless of FLT3 status were also detected. Although a direct relationship with FLT3 signaling was not suggested, these mutations have an essential role in maintaining leukemic clones by modulating epigenetic/transcriptional regulations (e.g., ASXL1, TET2, DNMT3A and STAG2), altering the metabolism of the citrate acid cycle (e.g., IDH1 and IDH2) and preventing apoptosis (e.g., TP53).
Biomedicines 08 00245 g003
Table
Table 1. FLT3 inhibitors.
Table 1. FLT3 inhibitors.
AgentGenerationTypeSelectivityIC50 (nM)Drug Sensitivity
ITDD835YITD-D835YF691L
Midostaurin(PKC412)FirstILow139SSRR
Sunitinib(SU11248)FirstILow250SRRR
Lestaurtinib(CEP701)FirstILow5SIntS−
Gilteritinib(ASP2215)SecondIModerate1.6SSIntR
Crenolanib(CP868596)SecondIModerate2SSIntR
Sorafenib(BAY43-9006)FirstIIModerate58SRRR
Tandutinib(CT53518)FirstIIHigh100SR−−
Quizartinib(AC220)SecondIIHigh<1.0SRRR
S (sensitive) means the IC50 is less than or equal to that of FLT3-ITD. R (resistant) means more than two folds increase in IC50. Int (intermediate) remains a 1.0–2.0-folds increase. Here is the reference of selectivity [60,61,62], IC50 for FLT3-ITD [47,49,63,64,65,66,67,68] and drug sensitivity [47,55,69,70,71,72].
Table
Table 2. Clinical results of FLT3 inhibitors.
Table 2. Clinical results of FLT3 inhibitors.
SORAFENIB (BAY 43-9006)
Authors and JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Rolling, et al. Lancet Oncol 2015SORAMLAML (age < 60)Newly diagnosedSorafenib + Standard therapyIICR60% (81/134)21 mo. [9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32]Not Reached (3-yr OS 63%)31% (42/132)
Uy, et al. Blood Advances 2016CALGB 11001AML (age > 60) with FLT3-ITD and/or TKDNewly diagnosedSorafenib + Standard therapyIICR74% (40/54)8.8 mo. (FLT3-ITD) 7.8 mo. (FLT3-TKD)15.0 mo. (FLT3-ITD) 16.2 mo. (FLT3-TKD)53% (22/54)
Ohanian, et al. Am J Hematol 2018−AML (age > 60) with FLT3-ITDNewly diagnosedSorafenib + AzacitidineI/IICR/Cri PR70% (19/27) 7% (2/27)7.1 mo. (only in responders)8.3 mo. (in all participants)11% (3/27)
Sasaki, et al. Cancer 2019−AML with FLT3-ITDNewly diagnosedSoragenib + Standard therapyRetrospectiveCR/CRi99% (78/79)31 mo. [5.7–56.8]17 mo. [11.1–22.4]67% (53/79)
Muppidi, et al. Clinical Lymphoma Myeloma and Leukemia 2015−AML with FLT3-ITDNewly diagnosed or relapsedSorafenib + DecitabineCase SeriesCR/CRi83% (5/6)Not Reported5.1 mo. [1.9–14.5]33% (2/6)
Ravandi, et al. Blood 2013−AML with FLT3-ITDRelapsed or refractory (including prior allo-SCT)Sorafenib + AzacitidineIICR/Cri PR43% (16/37) 3% (1/37)3.8 mo. [1.0–16.4]6.2 mo. 16% (6/37)
Bazarbachi, et al. Heamatologica 2019−AML with FLT3-ITDRelapsed ater allo-SCTSorafenib as part of/after salvageRetrospectiveCR39% (10/26)Not Reported(2-yr. OS 38%)13% (3/26)
MIDOSTAURIN (PKC412)
Authorsand JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Stone, et al. N Engl J Med 2017RATIFYAML with FLT3-ITD and/or TKDNewly diagnosedMidostaurin + Standard induction/consolidationIIICR70% (504/717)8.2 mo. [5.4–10.7]74.7 mo. [31.5–inf.]57% (287/504)
Schlenk, et al. Blood 2019AMLSG 16-10AML with FLT3-ITD and/or TKDNewly diagnosedMidostaurin + Standard induction/consolidation f/b Midostaurin maitenanceIICR/CRi76% (217/292)13.2 mo. [10.0–18.3]26.0 mo. [18.9–37.0]62% (134/217)
Fischer, et al. J Clin Oncol 2010−AML or high-risk MDSRelapsed or refractory or ineligible to standard therapyMidostaurinIIBPR HI Blast1% (1/97) 46% (16/35 *) 71% (25/35 *) * only in FLT3-mtNot Reported4.3 mo. [3.5–5.2]31% (42/132)
Strati, et al. Am J Hematol 2015−AML or high-risk MDSRelapsed or refractory or ineligible to standard therapyMidostaurin + AzacitidineI/IICR/Cri PR/MLFS15% (8/54) 13% (7/54)4.6 mo. [2.3–6.9] * Duration of Response5.1 mo. [3.5–6.7]0% (0/8)
Walker, et al. Leukemia & Lymphoma 2016−AMLRelapsed or refractory (including prior allo-SCT)Midostaurin + Bortezomib + Chemotherapy(MEC)ICR/CRi83% (19/23)Not Reported10.8 mo.63% (12/19)
Maziarz, et al. Blood 2018RADIUSAML with FLT3-ITDin 1st CR after allo-SCTMidostaurin + Standard of careIINot Applicable(18mo.-PFS 89%)Not ReportedNot Applicable
GILTERITINIB (ASP2215)
Authors and JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Perl, et al. N Engl J Med 2019ADMIRALAML with FLT3-ITD and/or TKDRelapsed or refractoryGilteritinibIIICR/Cri PR54% (134/247) 13% (33/247)2.8 mo. [1.4–3.7]9.3 mo. [7.7–10.7]26% (63/247)
Perl, et al. Lancet Oncol 2017−AML with FLT3-ITD and/or TKDRelapsed or refractoryGilteritinibI/IICR/Cri PR41% (69/169) 11% (19/169)4.6 mo. * Duration of Response7.1 mo.22% (37/169)
Usuki, et al. Cancer Science 2018−AMLRelapsed or refractoryGilteritinibICR/Cri PR60% (3/5 *) 20% (1/5 *) * only in FLT3-mt.Not ReportedNot ReportedNot Reported
QUIZARTINIB (AC220)
Authors and JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Altman, et al. Blood 2018−AMLNewly diagnosedQuizartinib + Standard induction/consolidation f/b Quizartinib maitenanceICR/CRi74% (14/19)(Maximum 16.3 mo.)Not Reported47% (9/19)
Cortes, et al. Blood 2019QuANTUM-RAML with FLT3-ITDRelapsed or refractoryQuizartinibIIICR/Cri48% (118/245)1.4 mo. [0.0–1.9]6.2 mo. [5.3–7.2]32% (78/245)
Cortes, et al. Blood 2018−AML with FLT3-ITDRelapsed or refractoryQuizartinibIIBCR/Cri PR47% (36/76) 18% (14/76)12.3 mo. [9.7–16.1]22.6 mo. [19.9–28.3]37% (28/76)
Cortes, et al. Lancet Oncol 2018−AMLRelapsed or refractoryQuizartinibIICR/Cri PR50% (125/248) 25% (62/248) * only in ITD-mt.2.8 mo. [1.4–3.6] * duration of CR, only in ITD-mt.5.8 mo. [4.9–6.8] * only in ITD-mt.35% (61/176)
Sandmaier, et al. Am J Hematol 2017−AML with FLT3-ITDin 1st CR after allo-SCTQuizartinib maintenanceINot Applicable(0.4–22.8 mo.) * duration of maitenance(3.0–32.7 mo.)Not Applicable
CRENOLANIB (CP868596)
Authors and JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Wang, et al. Blood 2016−AML with FLT3-ITD and/or TKDNewly diagnosedCrenolanib + Standard induction/consolidation f/b Crenolanib maintenanceIICR/CRi96% (24/25)Not ReportedNot Reached (6 mo. OS 85%)50% (12/24)
Randhawa, et al. Blood 2014−AML with FLT3-ITD and/or TKDRelapsed or refractoryCrenolanibIICR/Cri MLFS HI23% (3/13) 8% (1/13) 31% (4/13) * only in TKI-naïve3.0 mo. * only in TKI-naïve12.7 mo. * only in TKI-naïve26% (9/34)
Ohanian, et al. Blood 2016−AML with FLT3-ITD and/or TKDRelapsed or refractoryCrenolanib + Salvage chemotherapy (IDA/AraC)ICR/CRi36% (4/11)Not Reported8.5 mo.75% (3/4)
Iyer, et al. Blood 2016−AMLRelapsed or refractoryCrenolanib + Chemotherapy (HAM)ICR/CRi67% (4/6)Not ReportedNot Repoted25% (1/4)
LESTAURTINIB (CEP701)
Authors and JounalsTrial NameObjectivesDisease StatusAgents * Controls Not ShownPhase/DesignResponse RateMedian PFSMedian OSSequential allo-SCT
Levis, et al. Blood 2017−AML with FLT3-ITD and/or TKDRelapsedSlavage chemotherapy (MEC) f/b Lestaurtinib maintenanceIICR/CRi26% (29/112)Not Reported5.2 mo.20% (22/112)
Knapper, et al. Blood 2017−AML with FLT3-ITD and/or TKDNewly diagnosedStandard induction/consolidation f/b Lestaurtinib maintenanceIIICR/CRi92% (277/300)(5-yr. PFS 39–40%)(5-yr. OS 43–50%)21% (58/277)
Table
Table 3. Clinical trials of FLT3 inhibitors.
Table 3. Clinical trials of FLT3 inhibitors.
SORAFENIB (BAY 43-9006)
Trial NumberObjectivesDisease StatusAgents * Controls Not ShownPhase/Design
NCT01371981AML with FLT3-ITD (high allelic ratio)Newly diagnosedSorafenib + BertezomibIII
NCT03170895AML with FLT3-ITDNewly diagnosed or relapsedSorafenib + Homoharringtonine (STAT inhibitor)II
MIDOSTAURIN (PKC412)
NCT03686345Core binding factor AMLNewly diagnosedMidostaurin + Standard inductionII
NCT03280030AML with FLT3-ITD and/or TKDNewly diagnosedMidostaurin + Standard induction/consolidation f/b Midostaurin maitenanceII
NCT03512197AML with FLT3-ITD and/or TKDNewly diagnosedMidostaurin + Standard induction/consolidation f/b Midostaurin maitenanceIII
NCT03379727AML with FLT3-ITD and/or TKDNewly diagnosedMidostaurin + Standard induction/consolidation f/b Midostaurin maitenanceIII
GILTERITINIB (ASP2215)
NCT02236013AMLNewly diagnosedGilteritinib + Standard induction/consolidationI
NCT02752035AML with FLT3-ITD and/or TKDNewly diagnosed and ineligible to standard therapyGilteritinib + AzacitidineIII
NCT03730012AML with FLT3-ITD and/or TKDRelapsed or refractoryGilteritinib + Atezolizumab (anti-PD-L1 antibody)I/II
NCT02310321AMLNewly diagnosedGilteritinib + Standard induction/consolidationI/II
NCT03182244AML with FLT3-ITD and/or TKDRelapsed or refractoryGilteritinib + Salvage chemotherapyIII
QUIZARTINIB (AC220)
NCT02668653AML with FLT3-ITDNewly diagnosedQuizartinib + Standard induction/consolidationIII
NCT03723681AMLNewly diagnosedQuizartinib + Standard induction/consolidationI
NCT02834390AMLNewly diagnosedQuizartinib + Standard induction/consolidationIB
NCT03552029AML with FLT3-ITDRelapsed or refractory or ineligible to standard therapyQuizartinib + Milademetan (MDM2 inhibitor)I
NCT03135054AML with FLT3-ITDNewly diagnosed or relapsedQuizartinib + Homoharringtonine (STAT inihibitor)II
NCT03661307AML with FLT3-ITDNewly diagnosed or relapsedQuizartinib + Decitabine + Venetoclax (BCL-2 inhibitor)I/II
NCT03735875AML with FLT3-ITDRelapsed or refractoryQuizartinib + Venetoclax (BCL-2 inhibitor)IB/II
CRENOLANIB (CP868596)
NCT03258931AML with FLT3-ITD and/or TKDNewly diagnosedCrenolanib + Standard induction/consolidationIII
NCT02283177AML with FLT3-ITD and/or TKDNewly diagnosedCrenolanib + Standard inductionII
NCT03250338AML with FLT3-ITD and/or TKDRelapsed or refractoryCrenolanib + Salvage chemotherapyIII
NCT02400281AML with FLT3-ITD and/or TKDRelapsed or refractoryCrenolanib + Salvage chemo. or AzacitidineI/II
NCT02626338AMLRelapsed or refractoryCrenolanib + Salvage chemotherapyI/II
NCT01522469AML with FLT3-ITD and/or TKDRelapsed or refractoryCrenolanib + Standard induction/consolidationIB
OTHERS
NCT00783653AML with FLT3-ITD and/or TKDNewly diagnosedSunitinib + Standard inductionI/II
NCT00469859AML with FLT3-ITD and/or TKDRelapsed or refractoryLestaurtinib + Salvage chemotherapyI/II

Share and Cite

MDPI and ACS Style

Eguchi, M.; Minami, Y.; Kuzume, A.; Chi, S. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines 2020, 8, 245. https://doi.org/10.3390/biomedicines8080245

AMA Style

Eguchi M, Minami Y, Kuzume A, Chi S. Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Biomedicines. 2020; 8(8):245. https://doi.org/10.3390/biomedicines8080245

Chicago/Turabian Style

Eguchi, Motoki, Yosuke Minami, Ayumi Kuzume, and SungGi Chi. 2020. "Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia" Biomedicines 8, no. 8: 245. https://doi.org/10.3390/biomedicines8080245

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop